Neurogene (NGNE) Return on Equity (2014 - 2026)

Neurogene (NGNE) has 13 years of Return on Equity data on file, last reported at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.0%, down from 0.0% in the prior quarter.
• Across five years, Return on Equity topped out at 0.03% in Q4 2022 and bottomed at 0.37% in Q4 2023.
• The 5-year median for Return on Equity is 0.0% (2024), against an average of 0.02%.
• The widest annual swing landed in 2023, when Return on Equity slumped 40 bps; it then soared 37 bps in 2024.
• A 5-year view of Return on Equity shows it stood at 0.03% in 2022, then plunged by 1427 bps to 0.37% in 2023, then soared by 99 bps to 0.0% in 2024, then dropped by 4 bps to 0.0% in 2025, then dropped by 15 bps to 0.0% in 2026.
• The last three Return on Equity figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.

Peer Comparison